Human CD30/TNFRSF8 Protein
Catalog No: CD30-HF001
- Species
- Human
- Expression System
- HEK293
- Tag
- an hFc (IgG1)
- Activity
- Activity verified
Product overview
Recombinant Human CD30/TNFRSF8 Protein is expressed in HEK293 cells with an hFc (IgG1) tag at the C-terminus. It contains amino acid residues Phe19-Lys379 (UniProt accession: P28908-1).
Product Details
- Molecular Aliases
- CD30; CD30KI-1; CD30L receptor; TNFRSF8; D1S166EKi-1; CD30KI-1;CD30KI1; D1S166EKi1
- Protein Length
- Phe19-Lys379
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 65.2 kDa. Due to glycosylation, the protein migrates to 80-115 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE
- Endotoxin
- Less than 0.1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Human CD30 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
Immobilized Human CD30 Ligand, His Tag at 5μg/ml (100μl/well) on the plate. Dose response curve for Human CD30, hFc Tag with the EC50 of 3.8ng/ml determined by ELISA.
Immobilized Human CD30, hFc Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Anti-CD30 Antibody, hFc Tag with the EC50 of 5.3ng/ml determined by ELISA.
Background
The transmembrane receptor CD30 (TNFRSF8) and its ligand CD30L (CD153, TNFSF8) are members of the tumor necrosis factor (TNF) superfamily and display restricted expression in subpopulations of activated T-and B-cells in nonpathologic conditions. CD30 expression is upregulated in various hematological malignancies, including Reed-Sternberg cells in Hodgkin's disease (HD), anaplastic large cell lymphoma (ALCL) and subsets of Non-Hodgkin's lymphomas (NHLs).
References
- Oflazoglu E, Grewal IS, Gerber H. Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. Adv Exp Med Biol. 2009;647:174-85. doi: 10.1007/978-0-387-89520-8_12. PMID: 19760074.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.